On this news, Hims & Hers' stock price fell $22.24 per share, or 34.63%, to close at $41.98 per share on June 23, 2025.

The lawsuits follow an announcement by Novo Nordisk that it terminated its collaboration with the telehealth company due to concerns about Hims & Hers' sales and“deceptive” marketing of the weight ...

Investing.com -- Hims & Hers CEO Andrew Dudum has shared new information about the company’s terminated partnership with Novo Nordisk (NYSE: NVO ), which ended in June 2025, in an interview with The ...

The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its geographic reach.

If you wish to turn $10,000 into $50,000 by 2035, you’re looking at a 400% gain over a 10-year horizon. In the past decade, ...

One in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a ...

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

Danish pharmaceutical company Novo Nordisk has officially launched its once-weekly injectable weight management drug, Wegovy® ...

Imugene is tapping the market for up to $35 million, while Clever Culture Systems and Compumedics are soaring on positive ...

NVIDIA Corporation (NASDAQ:NVDA) is one of the. NVIDIA Corporation (NASDAQ:NVDA) announced a collaboration with Novo Nordisk ...